Together with the new SITUS BW 28D left ventricle pacing lead and lead delivery system, Paradym CRT forms a complete new CRT system for heart failure patients, the company said.
Paradym CRT is said to be designed to allow more flexibility in the management of cardiac resynchronization and anti-tachyarrhythmia therapy in heart failure patients, due to the unique Brady-Tachy Overlap (BTO) feature.
Fred Hrkac, president of the CRM business unit at Sorin Group, said: “Sorin Group is delighted to announce the launch of Paradym CRT. The device provides patients the highest delivered energy available on the market to date in a 34cc small and long-lasting device. With Paradym CRT, patients have the opportunity to exercise, while arrhythmias at all different rates can be accurately treated.
“Paradym CRT is the first device of a novel Sorin Group platform which will bring a wide range of treatment options for physicians and patients, further strengthening our innovative leadership in the hemodynamic management of heart failure.”